GLYCERYL TRINITRATE WOCKHARDT

glyceryl trinitrate 50mg/50mL

The AVAILABLE
GTN 50mg/50ml





50mg

in 50mL glass vial

- First available 50mg/50mL GTN solution in Australia
- The only ethanol free GTN formulation
- Facilitates dose flexibility
- Improved convenience of dose preparation and administration
- Proven supply record
- Cost effective



Distributed in Australia by: Wockhardt Bio Pty Ltd c/o InterPharma Pty Ltd Suite 103 / 39 East Esplanade Manly NSW 2095 Ph: 02 9976 6876 www.interpharma.com.au

GLYCERYL TRINITRATE WOCKHARDT

glyceryl trinitrate 50mg/50mL

Active Ingredient	Glyceryl trinitrate
Excipients	Glucose, Glucose monohydrate, Propylene glycol
Immediate Container	50mL colourless glass vials
Strength	Each 50mL of GLYCERYL TRINITRATE WOCKHARDT contains 50mg of Glyceryl trinitrate. The solution is preservative free.
Pack Size	Presented in packs of 1 x 50mL glass vial
Stability Unopened	2 years, store below 25°C, protect from light
Stability After 1st Opening	Once the vial has been opened, the product must be used immediately

Before prescribing, please review full Product Information (PI) available on request from InterPharma.

GLYCERYL TRINITRATE WOCKHARDT (Glyceryl trinitrate 50mg/50mL) CONCENTRATED solution for Injection Minimum Product Information: Indications: Blood pressure control in perioperative hypertension: congestive heart failure due to acute myocardial infarction; angina pectoris in patients non-responsive to organic nitrates/beta blocker; controlled hypertension in neurosurgical/ orthopaedic surgery procedures. Contraindications: Hypersensitivity to glyceryl trinitrate/organic nitrates or excipients; hypotension/ uncorrected hypovolemia; increased intracranial pressure; constrictive pericarditis and pericardial tamponade; severe anaemia or arterial hypoxaemia; coadministration of sildenafil and soluble guanylate cyclase stimulator; obstructive cardiomyopathy (especially with aortic or mitral stenosis/constrictive pericarditis). Precautions: Not for intravenous injection; dilute in 5% glucose OR 0.9% sodium chloride preinfusion; administration set used affects active amount delivered; only use in acute myocardial infarction for treating definite left ventricular failure; careful dose titration required to avoid precipitous blood pressure decrease; avoid excess hypotension and for prolonged periods; vasodilators use in hypertensive patients suspected of causing acute blindness; tolerance/cross tolerance may occur with long term/ repeated use of organic nitrates; nitrate dependence; caution in patients with severe ischaemic heart disease/pulmonary disease due to hypoxaemia; methaemoglobinaemia; patients with malnutrition, hypothermia, hypothyroidism, hyperthyroidism, severe hepatic/renal disease, elderly patients; not recommended in children; contains glucose; may affect certain laboratory tests (refer PI for details). Interactions: Alcohol, levodopa, pancuronium, morphine, ergot alkaloids, tricyclic antidepressants, anticholinergics, vasodilators, antihypertensives, major tranquillisers, opioids; aspirin, non-steroidal anti-inflammatory drugs, noradrenaline, sympathomimetics, heparin. Pregnancy Category B2; Caution with lactation. Adverse Events: Generally dose related; headache, tachycardia, nausea, vomiting, apprehension, restlessness, muscle twitching, retrosternal discomfort, palpitations, dizziness and abdominal pain; hypotension, bradycardia; hyperosmolarity due to propylene glycol solvent. Dosage: Initially 5µg/min (for non-absorbing tubing) then titrated at 5µg/min increments every 3-5 mins according to clinical situation and until response noted. If no response at 20µg/min, use 10µg/min then 20µg/min increments. Once partial response observed, reduce dose increase and lengthen dosage increment interval. No fixed optimum dose; continuous monitoring of physiologic parameters required. Administration: Initial dilution in 450mL of 5% glucose or 0.9% sodium chloride for final concentration of 100 µg/mL. Refer PI for maintenance dilution instructions. Based on Product Information dated 7 May 2019.



Distributed in Australia by: Wockhardt Bio Pty Ltd c/o InterPharma Pty Ltd Suite 103 / 39 East Esplanade Manly NSW 2095 Ph: 02 9976 6876 www.interpharma.com.au

Date of first approval: 7th May 2019